Filing Flows › CytomX Therapeutics (CTMX) › Recalls, complaints & regulation
CytomX Therapeutics (CTMX): clinical trials
CytomX Therapeutics (CTMX) beyond its filings: 3 active clinical trials.
CytomX Therapeutics' latest quarter
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does CytomX Therapeutics have?
3 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.